AbbVie의 최근 종양 부문의 최신정보는 임상면의 기세와 연구자의 참여가 지속되고 있음을 나타내며, 지속적인 채택의 가능성을 뒷받침하고 있습니다.
6. 경쟁 우위와 시장 동향
EMRELIS의 ADC 설계는 강력한 세포독성 페이로드의 표적 전달을 가능하게 하며, 기존의 화학요법과 일부 표적 치료제와의 차별화를 실현하고 있습니다.
바이오마커에 기반한 접근법은 임상적 효과의 가능성을 높이고 정밀암 치료의 동향에 따른 것입니다.
ADC 플랫폼의 성장, 개인화 암 치료, 병용 요법 등 보다 광범위한 시장 역학이 EMRELIS의 포지셔닝을 지원하고 있습니다.
종양학 부문에서 실제 임상 증거(RWE)에 대한 의존도 증가는 광범위한 임상 적용 후 지불자 및 처방자의 신뢰도를 강화할 것으로 예상됩니다.
본 보고서는 주요 7개국(미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국)에서 비소세포 폐암과 같은 승인된 적응증에 대한 EMRELIS의 종합적인 인사이트를 제공합니다. 본 보고서는 2020년부터 2034년까지의 조사 기간 동안 주요 7개국 시장에서 EMRELIS의 사용 상황, 예상 진입 상황, 승인된 적응증의 실적에 대한 상세한 분석을 제공하고, 승인된 적응증에 대한 EMRELIS의 상세한 설명을 기재하고 있습니다. 또한 EMRELIS의 판매 예측, 작용기전(MoA), 투여량 및 투여 방법, 규제상의 이정표를 포함한 R&D 및 기타 개발 활동에 대한 인사이트를 제공합니다. 또한 과거 EMRELIS 실적과 현재 상황, 미래 시장 평가, SWOT 분석, 분석가 견해, 경쟁업체의 종합적 개요, 각 적응증에 대한 기타 신흥 치료법에 대한 개요도 포함되어 있습니다. 또한 EMRELIS의 매출 예측 분석, 시장 주도 요인 등도 정리했습니다.
목차
제1장 보고서 개요
제2장 비소세포 폐암 등의 승인된 적응증에 대한 EMRELIS의 개요
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 프로파일
제3장 EMRELIS : 경쟁 구도(시판 중인 치료제)
제4장 EMRELIS : 경쟁 구도(개발 후기 치료제)
제5장 EMRELIS : 시장 평가
승인된 적응증에 대한 시장 전망
주요 7개국 분석
승인된 적응증에 대한 주요 7개국 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 EMRELIS : SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 정보
제12장 보고서 구매 옵션
HBR
영문 목차
영문목차
Key Factors Driving EMRELIS Growth
1. Market Share Gains and New Patient Starts
EMRELIS is positioned as a targeted ADC option for patients with biomarker-defined solid tumors, addressing areas of high unmet need where standard therapies provide limited benefit.
New patient starts are expected to grow as oncologists increasingly adopt biomarker-guided treatment strategies and integrate ADCs earlier in treatment sequences.
Clinical interest is supported by meaningful antitumor activity observed in selected patient populations, reinforcing confidence among treating physicians.
AbbVie's oncology-focused commercial and medical engagement, including biomarker education and specialist outreach, is expected to drive adoption post-approval.
2. Expansion Across Key Indications
Non-Small Cell Lung Cancer (NSCLC): EMRELIS is primarily being developed for c-Met-overexpressing NSCLC, particularly in patients who have progressed on prior lines of therapy.
Biomarker-Defined Solid Tumors: Beyond NSCLC, EMRELIS has potential applicability in other c-Met-expressing tumors, expanding the addressable patient population.
Later-Line and Refractory Settings: The drug is positioned to fill a critical gap for patients with limited treatment options after chemotherapy, immunotherapy, or targeted agents.
Pipeline and lifecycle expansion opportunities, including combination strategies, may further broaden EMRELIS's clinical and commercial reach.
3. Geographic Expansion
EMRELIS is being advanced with a global development and commercialization strategy, targeting major oncology markets such as the United States, Europe, and Asia.
The Asia-Pacific region represents a significant growth opportunity, driven by high lung cancer prevalence, increasing access to biomarker testing, and rapid uptake of novel oncology agents.
AbbVie's established global oncology infrastructure and regional partnerships are expected to support efficient market entry and uptake.
4. New Indication Approvals
Regulatory progress for EMRELIS in NSCLC would significantly broaden AbbVie's oncology portfolio, particularly in precision oncology.
Future approvals in additional biomarker-defined indications could diversify revenue streams and strengthen competitive positioning in the expanding ADC market.
Given the high unmet need in c-Met-driven cancers, EMRELIS may benefit from regulatory flexibility or expedited pathways in select indications.
5. Strong Momentum in Lung Cancer Segments
Lung cancer remains a major volume driver, with large patient populations and continued demand for effective post-immunotherapy treatment options.
Increasing routine use of biomarker testing (including c-Met expression) is improving patient identification and supporting treatment uptake.
AbbVie's recent oncology updates highlight continued clinical momentum and investigator engagement, supporting sustained adoption potential.
6. Competitive Differentiation and Market Trends
EMRELIS's ADC design enables targeted delivery of a potent cytotoxic payload, differentiating it from conventional chemotherapy and some targeted agents.
A biomarker-driven approach enhances the likelihood of clinical benefit and aligns with precision oncology trends.
Broader market dynamics-such as growth in ADC platforms, personalized cancer therapy, and combination regimens-support EMRELIS's positioning.
Increasing reliance on real-world evidence (RWE) in oncology is expected to strengthen payer and prescriber confidence following broader clinical use.
EMRELIS Recent Developments
In May 2025, AbbVie announced that EMRELIS (telisotuzumab vedotin-tllv) had been granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein overexpression is defined as >= 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test.
"EMRELIS Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of EMRELIS for approved indication like Non-small cell lung cancer in the 7MM. A detailed picture of EMRELIS's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the EMRELIS for approved indications. The EMRELIS market report provides insights about EMRELIS's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current EMRELIS performance, future market assessments inclusive of the EMRELIS market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of EMRELIS sales forecasts, along with factors driving its market.
EMRELIS Drug Summary
EMRELIS is a c-Met-directed antibody-drug conjugate (ADC) containing telisotuzumab vedotin-tllv, consisting of a humanized IgG1-kappa monoclonal antibody targeting the c-Met receptor covalently linked to monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. It binds to c-Met overexpressed on tumor cells, such as in non-squamous non-small cell lung cancer (NSCLC), undergoes internalization, releases MMAE in lysosomes, and inhibits microtubule polymerization, leading to G2/M phase arrest and apoptosis. FDA-approved on May 2025, for adults with locally advanced or metastatic non-squamous NSCLC with high c-Met overexpression (>=50% tumor cells with 3+ staining, confirmed by FDA-approved test), it is administered intravenously at 2.4 mg/kg every 3 weeks after reconstitution and dilution in 0.9% sodium chloride. The report provides EMRELIS's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the EMRELIS Market Report
The report provides insights into:
A comprehensive product overview including the EMRELIS MoA, description, dosage and administration, research and development activities in approved indication like Non-small cell lung cancer.
Elaborated details on EMRELIS regulatory milestones and other development activities have been provided in EMRELIS market report.
The report also highlights EMRELIS's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
The EMRELIS market report also covers the patents information, generic entry and impact on cost cut.
The EMRELIS market report contains current and forecasted EMRELIS sales for approved indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The EMRELIS market report also features the SWOT analysis with analyst views for EMRELIS in approved indications.
Methodology:
The EMRELIS market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
EMRELIS Analytical Perspective by DelveInsight
In-depth EMRELIS Market Assessment
This EMRELIS sales market forecast report provides a detailed market assessment of EMRELIS for approved indication like Non-small cell lung cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted EMRELIS sales data uptil 2034.
EMRELIS Clinical Assessment
The EMRELIS market report provides the clinical trials information of EMRELIS for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
EMRELIS Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
EMRELIS Market Potential & Revenue Forecast
Projected market size for the EMRELIS and its key indications
Commercial partnerships, licensing deals, and M&A activity
EMRELIS Clinical Differentiation
EMRELIS Efficacy & safety advantages over existing drugs
EMRELIS Unique selling points
EMRELIS Market Report Highlights
In the coming years, the EMRELIS market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The EMRELIS companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EMRELIS's dominance.
Other emerging products for Non-small cell lung cancer are expected to give tough market competition to EMRELIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EMRELIS in approved indications.
Analyse EMRELIS cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted EMRELIS sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of EMRELIS in approved indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of EMRELIS? How strong is EMRELIS's clinical and commercial performance?
What is EMRELIS's clinical trial status in each individual indications such as Non-small cell lung cancer and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EMRELIS Manufacturers?
What are the key designations that have been granted to EMRELIS for approved indications? How are they going to impact EMRELIS's penetration in various geographies?
What is the current and forecasted EMRELIS market scenario for approved indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of EMRELIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to EMRELIS for approved indications?
Which are the late-stage emerging therapies under development for the treatment of approved indications?
How cost-effective is EMRELIS? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. EMRELIS Overview in approved indications like Non-small cell lung cancer
